

September 25, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Growth)

Shinya Kurebayashi, President & CEO

## Announcement of Receiving Manufacturing and Sales Approval for biosimilar in the Oncology in Japan (Excerpt from Japanese version)

Tokyo, September 25, 2023 – Kidswell Bio Corporation (“KWB”) has been collaborating with Mochida Pharmaceutical Co., Ltd. based on the joint development agreement for the biosimilar in the oncology (Project name: GBS-010, Pegfilgrastim biosimilar) executed on December 5, 2016, and Mochida Pharmaceutical Co., Ltd. has received approval of manufacturing and sales in Japan from the Ministry of Health, Labour and Welfare on September 25, 2023.

It is the fourth product to launch in the biosimilar business following Filgrastim BS, Darbepoetin Alpha BS and Ranibizumab BS. Besides the revenues from these biosimilars, by leveraging the know-how and expertise about biotechnology acquired in the past business activities, we will continue focusing on the accomplishment of the medium-term strategic plan, KWB 2.0, and further business growth.

The impact on the business results for the fiscal year ending March 2024 has already been incorporated into the initial plan, and there are no revisions to the financial forecast at this time.

### About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children’s potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under “Kids Well, All Well.”

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: [info@kidswellbio.com](mailto:info@kidswellbio.com)